CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation
Top Cited Papers
Open Access
- 26 September 2013
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 369 (13) , 1227-1236
- https://doi.org/10.1056/nejmoa1303688
Abstract
The use of available antiviral agents for the prevention of cytomegalovirus (CMV) disease is limited by frequent toxic effects and the emergence of resistance. CMX001 has potent in vitro activity against CMV and other double-stranded DNA viruses. We evaluated the safety and anti-CMV activity of CMX001 in patients who had undergone allogeneic hematopoietic-cell transplantation.Keywords
This publication has 30 references indexed in Scilit:
- Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2012
- Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trialThe Lancet Infectious Diseases, 2011
- How we treat cytomegalovirus in hematopoietic cell transplant recipientsBlood, 2009
- Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the artAntiviral Research, 2009
- Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysisBlood, 2007
- The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapyBlood, 2004
- Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategiesTransplantation and Cellular Therapy, 2003
- Increased Antiviral Activity of 1-O-Hexadecyloxypropyl-[2-14C]cidofovir in MRC-5 Human Lung Fibroblasts Is Explained by Unique Cellular Uptake and MetabolismMolecular Pharmacology, 2003
- Ganciclovir Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Bone Marrow Transplant Recipients: Results of a Placebo-Controlled, Double-Blind TrialAnnals of Internal Medicine, 1993
- Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow TransplantAnnals of Internal Medicine, 1993